Copyright
©The Author(s) 2018.
World J Gastrointest Oncol. Oct 15, 2018; 10(10): 282-289
Published online Oct 15, 2018. doi: 10.4251/wjgo.v10.i10.282
Published online Oct 15, 2018. doi: 10.4251/wjgo.v10.i10.282
Table 3 Immunotherapy studies
| Ref. | Patient No. | Treatment group(s) | Intraperitoneal regimen | Systemic regimen | Outcomes | |
| Heiss et al[45], 2010 | 66 | Paracentesis + catumaxomab vs Paracentesis alone | Catumaxomab | - | Paracentesis Alone Median OS: 44 d | Paracentesis + Catumaxomab Median OS: 71 d |
| Bokemeyer et al[46], 2015 | 54 | NA chemotherapy, surgery, intra- and post-op catumaxomab | Catumaxomab | Variable | 4 yr DFS: 38% 4 yr OS: 50% | |
- Citation: Leiting JL, Grotz TE. Optimizing outcomes for patients with gastric cancer peritoneal carcinomatosis. World J Gastrointest Oncol 2018; 10(10): 282-289
- URL: https://www.wjgnet.com/1948-5204/full/v10/i10/282.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v10.i10.282